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ARTICLE OPEN
Association of dementia with immunoglobulin G N-glycans in
a Chinese Han Population
Xiaoyu Zhang1,2,9, Hui Yuan3,9, Jihui Lyu4,9, Xiaoni Meng1, Qiuyue Tian1, Yuejin Li5, Jie Zhang1, Xizhu Xu5, Jing Su6, Haifeng Hou5,
Dong Li5, Baoliang Sun7, Wei Wang 1,5,8✉ and Youxin Wang 1,8✉
Immunoglobulin G (IgG) functionality can drastically change from anti- to proinflammatory by alterations in the IgG N-glycan
patterns. Our previous studies have demonstrated that IgG N-glycans associated with the risk factors of dementia, such as aging,
dyslipidemia, type 2 diabetes mellitus, hypertension, and ischemic stroke. Therefore, the aim is to investigate whether the effects of
IgG N-glycan profiles on dementia exists in a Chinese Han population. A case–control study, including 81 patients with dementia,
81 age- and gender-matched controls with normal cognitive functioning (NC) and 108 non-matched controls with mild cognitive
impairment (MCI) was performed. Plasma IgG N-glycans were separated by ultra-performance liquid chromatography. Fourteen
glycan peaks reflecting decreased of sialylation and core fucosylation, and increased bisecting N-acetylglucosamine (GlcNAc)
N-glycan structures were of statistically significant differences between dementia and NC groups after controlling for confounders
(p < 0.05; q < 0.05). Similarly, the differences for these 14 initial glycans were statistically significant between AD and NC groups after
adjusting for the effects of confounders (p < 0.05; q < 0.05). The area under the receiver operating curve (AUC) value of the model
consisting of GP8, GP9, and GP14 was determined to distinguish dementia from NC group as 0.876 [95% confidence interval (CI):
0.815–0.923] and distinguish AD from NC group as 0.887 (95% CI: 0.819–0.936). Patients with dementia were of an elevated
proinflammatory activity via the significant changes of IgG glycome. Therefore, IgG N-glycans might contribute to be potential
novel biomarkers for the neurodegenerative process risk assessment of dementia.
npj Aging and Mechanisms of Disease             (2021) 7:3 ; https://doi.org/10.1038/s41514-021-00055-w
INTRODUCTION
Dementia is a major global challenge for health and social care in
the 21st century. It occurs mainly in subjects older than 65 years,
making them gradually lose their abilities and become more
dependent1. Alzheimer disease (AD) is the most common form of
dementia, accounting for approximately 60–80% of all types1. The
concept of mild cognitive impairment (MCI) is as an intermediate
state between normal cognition and dementia; nevertheless,
the boundary between the MCI and dementia is gray2. Research
has found that potentially modifiable risk factors of worldwide
dementia, mainly vascular risk factors, account for 40% (hyperten-
sion, obesity, diabetes, later-life smoking, depression, physical
inactivity, etc.)3,4. Besides, increasing age is also one of the
strongest known risk factors for dementia5,6. During the process of
senescence, cells secrete a large number of inflammatory factors
and chemokines, such as interleukin-6 (IL-6), interleukin-1 beta (IL-
1β), and tumor necrosis factor-alpha (TNF-α), which can produce
chronic inflammatory responses5,7. Accumulating evidence has
suggested that inflammatory responses make a valuable con-
tribution towards the neurodegenerative cascades of dementia
and MCI, and several markers were found to be able to accurately
detect the disease severity and progression8–12. The mechanisms
of dementia, however, are still largely unknown.
Glycosylation is a complex post-translational modification
during gene expression involved in more than half of all
mammalian proteins13. Glycan binding in functional proteins has
a crucial role in the biological processes of molecular recognition
and adhesion, cell signaling or immunological response14,15.
Hence, molecular defects in glycan synthesis are recognized as
direct causes of an increasing number of diseases16,17. Immuno-
globulin G (IgG) exerts the role in the immune system the body18.
In terms of its characteristic of structure with conserved N-
glycosylation in Fc, so IgG is one of the mostly suitable choices for
glycoproteins research19. The attachment of different glycans
displays conformational flexibility and plasticity which can be
dramatically influence on IgG effector functions15. In particular, the
glycan portion of IgG critically affects immune effector functions
mediated by the Fc receptor and complement C1q20. It modulates
in relation to current physiological conditions, but can also change
in an “on and off mode” during acute inflammation21. Hence,
changes in IgG glycosylation not only participate in many kinds of
inflammatory diseases22–25, but also the molecular mechanism
may give rise to the promotion of inflammation21,26,27.
Considering the fact that the inflammatory role of IgG N-
glycosylation and its association with the risk factors of dementia
[such as aging, central obesity, dyslipidemia, type 2 diabetes
mellitus (T2DM), hypertension, and ischemic stroke]28–34, we
hypothesized that these associations might provide a possible
explanation for the pathogenesis of dementia in a Chinese Han
population. In addition, previous study provided the evidence in
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European ancestry individuals that a lower abundance of complex
galactosylation and sialylation played a role in the development of
AD35. Therefore, the aim is to explore whether the changes in IgG
glycosylation can identify specific alterations for dementia
progress in a Chinese Han population and reveal dementia
potential pathogenesis. Meanwhile, we investigate the associa-
tions between IgG N-glycan profiles and inflammation factors
including anti-inflammatory (IL-4 and IL-10) and proinflammatory
factors [IL-1β, IL-6, CRP, TNF-α, and interferon-gamma (IFN-γ)],




In total, 81 patients with dementia, 81 age- and gender-matched
participants with NC and 108 non-matched participants with MCI
were included in the present study. The 81 dementia partici-
pants consisted of 47 (58.00%) AD, 18 (22.20%) vascular
dementia (VaD), and 16 (19.80%) other type of dementia. The
differences of demographic characteristics and inflammatory
factors among three groups were presented in Table 1 and Fig. 1.
The median ages for three groups were 82, 80, and 76 years,
respectively. The number of females was generally higher than
males for each group, but it was not statistically significant
among three groups. The values of TC and LDL-C in the
dementia group were significantly lower than these in the NC
group (p < 0.017). In addition, age in the dementia group was
significantly higher than that in the MCI group, whereas values of
systolic blood pressure (SBP) and diastolic blood pressure (DBP)
were lower than these in the MCI group (p < 0.017). The levels of
SBP, DBP, TC, and LDL-C of MCI group were significantly higher
than NC group (p < 0.017).
The levels of CRP, TNF-α, and IFN-γ were of significant
differences among three groups, whereas the levels of IL-1β, IL-4,
IL-6, and IL-10 were not of significant differences (p < 0.05) (Fig. 1).
IgG glycome compositions
Of the 22 initial glycans, 18 were significantly skewed (p < 0.05)
(Supplementary Table 3). The comparisons of initial glycans
compositions among dementia, MCI and NC groups were
shown in Table 2, while these of derived traits were shown in
Supplementary Table 4. After adjusting for BMI, levels of
education, history of malignant tumor, habit of salt intake,
ischemic stroke, diabetes, hypertension, and dyslipidemia in the
logistic regression, 14 initial glycans (increased relative abundance
of GP1, GP2, GP5, GP7, GP8, GP9, GP10, GP12, GP13, GP15, and
GP22 as well as reduced relative abundance of GP14, GP16, and
GP18) remained significantly different between dementia and NC
groups (p < 0.05; q < 0.05) (Table 3 and Supplementary Fig. 1).
Derived glycan traits were of significant differences in patients
with dementia compared to NC group, primarily reflecting the
decreased of sialylation and core fucosylation, as well as the
increased bisecting N-acetylglucosamine (GlcNAc) N-glycan struc-
tures in dementia patients (Fig. 2 and Supplementary Table 5).
Similarly, these 14 initial glycans were significantly different
between AD and NC groups after adjusting for the effects of
above confounders (p < 0.05; q < 0.05) (Supplementary Table 6
and Supplementary Fig. 1). In addition, 7 initial glycans (increased
relative abundance of GP8, GP9, GP12, GP21, and GP23 as well as
reduced relative abundance of GP16 and GP18) were of significant
differences between dementia and MCI groups after adjusting
these confounders (p < 0.05; q < 0.05) (Table 3). Twelve IgG glycans
(increased relative abundance of GP1, GP2, GP5, GP7, GP10, GP11,
GP13, GP15, and GP22 as well as reduced relative abundance of
GP14, GP17, and GP23) were of significant differences between
MCI and NC groups after adjusting for these confounders (p < 0.05;
q < 0.05) (Table 3).
The dimension reduction and diagnostic values of IgG N-
glycans
As shown in Fig. 3, the significant correlations among glycans
indicated that multicollinearity might exist (p < 0.05). GP8, GP9,
and GP14 were selected by intersection of dimension reduction
methods [the Ridge and Stepwise (including the direction of
Forward and Backward) based on logistic regression as well as
Lasso regression], and thus were identified as a biomarker panel
for the diagnosis of dementia (Supplementary Table 7). Figure 4
showed the distribution of these three glycans for dementia, MCI,
and NC groups. Models were trained and evaluated using 5-fold
cross-validation in which random forest classifier was applied. The
AUC value of the model including GP8, GP9, and GP14 was
determined to distinguish dementia from NC groups as 0.876
(95% confidence interval [CI]: 0.815–0.923). Furthermore, this
model was also able to distinguish AD from NC groups with an
AUC of 0.887 (95% CI: 0.819–0.936), to distinguish dementia from
MCI groups with an AUC of 0.815 (95% CI: 0.752–0.868), to
distinguish MCI from NC groups with an AUC of 0.640 (95% CI:
0.568–0.709), respectively (Fig. 5). This model was of high accuracy
to predict by performing the random forest classifier for different
train datasets [normalized mean square error (NMSE) = 1.131,
mean squared error (MSE)= 0.124, and mean absolute error
(MAE)= 0.264 for dementia vs. NC; NMSE= 0.976, MSE= 0.075,
and MAE= 0.218 for AD vs. NC; NMSE= 3.373, MSE= 0.224, and
MAE= 0.401 for dementia vs. MCI; NMSE= 7.322, MSE= 0.234,
and MAE= 0.445 for MCI vs. NC] (Supplementary Table 8). In
addition, the panels of biomarkers were selected by intersection of
three methods to reduce dimension for AD vs. NC, dementia vs.
MCI, MCI vs. NC, and AD vs. MCI, respectively (Supplementary
Tables 9–12). The AUCs showed high accuracy for diagnostic
models in every two groups (Supplementary Table 13 and
Supplementary Fig. 2).
Correlation between IgG glycosylation and inflammation
factors
The spearman correlation coefficients between N-glycans and
inflammation factors were shown in Table 4. The anti-
inflammatory (IL-4 and IL-10) state was positively correlated with
GP8, GP10, and GP14 (p < 0.05). The proinflammation (CRP, TNF-α,
and IFN-γ) factors were positively correlated with GP8 and GP10,
whereas negatively correlated with GP16 (p < 0.05).
DISCUSSION
In this study, we systematically investigated IgG N-glycan profiles
in a case–control study including 81 dementia, 108 MCI, and 81 NC
participants. To the best of our knowledge, the present study is
the first study to assess the possible association between
dementia and IgG glycosylation in Chinese Han population. The
results demonstrated that 14 initial GPs reflecting the decreased
of sialylation and core fucosylation, as well as the increased
bisecting GlcNAc N-glycan structures were significantly associated
with dementia after adjusting the effects of confounders.
Diagnostic model including GP8, GP9, and GP14 was of promising
capability to distinguish dementia from NC group with an AUC of
0.876 (95% CI: 0.815–0.923) and distinguish AD from NC group
with an AUC of 0.887 (95% CI: 0.819–0.936) under 5-fold cross-
validation random forest classifiers.
Dementia is a multifactorial disease driven by many diverse risk
factors, including genetic variants, demographic risk factors (such
as aging and gender), modifiable risk factors (central obesity,
dyslipidemia, T2DM, hypertension, and ischemic stroke, etc.)36.
Cumulative evidence indicates that variations in IgG Fc N-glycome
X. Zhang et al.
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Fig. 1 The scatter plots of different levels of inflammatory factors among dementia, MCI, and NC groups. The scatter plots show the
different levels of anti-inflammatory and proinflammatory factors in dementia (orange), MCI (green), and NC (purple) groups. Anti-
inflammatory factors include IL-4 and IL-10, while proinflammatory factors include IL-1β, IL-6, CRP, IFN-γ, and TNF-α. *There were significant
differences between the two groups (p < 0.017); **There are significant differences for the trend tests (p < 0.05). NC normal cognitive
functioning, MCI mild cognitive impairment, IL-4 interleukin-4, IL-10 interleukin-10, IL-1β interleukin-1 beta, CRP C-reactive protein, IFN-γ
Interferon-gamma, TNF-α tumor necrosis factor alpha.
Table 2. The levles of initial glycans from NC, MCI, and dementia patients.
GPs NC (n= 81) MCI (n= 108) Dementia (n= 81) p*
Median (P25–P75) Median (P25–P75) Median (P25–P75)
GP1 0.05 (0.02–0.20) 0.37 (0.16–0.60) 0.33 (0.22–0.57)#$ <0.001
GP2 0.28 (0.10–0.45) 0.37 (0.17–0.73) 0.45 (0.24–0.78)#$ 0.001
GP4 42.02 (34.75–47.92) 41.59 (34.85–47.32) 39.16 (34.28–45.70)a 0.575
GP5 0.00 (0.00–0.02) 0.05 (0.01–0.17) 0.20 (0.07–0.36)#&$ <0.001
GP6 6.22 (4.76–7.78) 6.23 (5.17–7.52) 6.51 (5.21–7.73)a 0.937
GP7 0.01 (0.00–0.05) 0.14 (0.05–0.27) 0.15 (0.05–0.40)#$ <0.001
GP8 11.53 (10.35–12.87) 12.35 (10.02–13.91) 14.46 (13.11–15.57)#& <0.001
GP9 2.97 (1.72–4.64) 3.35 (2.00–5.06) 4.29 (3.29–5.58)#& <0.001
GP10 0.73 (0.52–1.13) 1.11 (0.57–1.93) 2.12 (1.19–2.87)#&$ <0.001
GP11 0.08 (0.06–0.23) 0.31 (0.14–0.60) 0.10 (0.05–0.31)&$ <0.001
GP12 0.14 (0.04–0.32) 0.16 (0.08–0.31) 0.32 (0.17–0.58)#& <0.001
GP13 0.14 (0.04–0.32) 0.31 (0.15–0.76) 0.36 (0.25–0.73)#$ <0.001
GP14 13.73 (11.43–17.54) 13.02 (8.74–16.56) 11.24 (7.89–14.26)a# 0.001
GP15 0.11 (0.06–0.18) 0.21 (0.11–0.43) 0.45 (0.23–0.68)#&$ <0.001
GP16 3.97 (2.96–4.64) 3.66 (2.99–4.49) 2.93 (2.34–3.46)a#& <0.001
GP17 0.83 (0.51–1.20) 0.56 (0.34–0.90) 0.75 (0.57–1.12)&$ <0.001
GP18 10.52 (7.73–13.29) 9.27 (7.75–12.12) 7.2 (5.89–9.06)#& <0.001
GP19 1.76 (1.28–2.24) 1.86 (1.31–2.42) 1.77 (1.29–2.12) 0.429
GP21 0.23 (0.17–0.31) 0.18 (0.13–0.26) 0.32 (0.23–0.53)#&$ <0.001
GP22 0.07 (0.46–0.14) 0.14 (0.07–0.27) 0.11 (0.08–0.24)#$ <0.001
GP23 0.67 (0.42–1.03) 0.53 (0.34–0.82) 0.84 (0.50–1.10)&$ <0.001
GP24 0.82 (0.59–1.33) 0.83 (0.49–1.21) 0.76 (0.47–1.05) 0.449
NC normal cognitive functioning, MCI mild cognitive impairment.
*p < 0.05 was considered statistically significant.
#p < 0.017, Dementia group compared with NC group.
$p < 0.017, MCI group compared with NC group.
&p < 0.017, Dementia group compared with MCI group.
aAnalysis of variance (ANOVA).
X. Zhang et al.
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play an important role in the anti-inflammatory or proinflamma-
tory process37. Our previous studies have shown that the
decreasing sialylation and the increasing bisecting GlcNAc are
associated with risk factors of dementia, which are consistent with
this study28,30–34,38–40. Therefore, aberrant glycosylation of IgG
related to dementia implied a proinflammatory status in the
participants with dementia in this study.
The associations between IgG Fc N-glycans and neurodegen-
erative diseases have been observed in previous studies35,41–43.
Gizaw et al found that the fucose and bisecting-GlcNAc structures
were significantly increased while disialylated N-glycans were
decreased in AD patients’ serum when compared with the normal
control group41. Maguire et al found that a significant decrease in
soluble sialyltransferase activity in serum was reported in a study
comparing 12 AD patients with 12 age-matched controls42.
Lundström et al reported an increased FA2 (named GP4 in the
present study) and a reduced FA2G1 (GP8 or GP9), FA2G2 (GP14),
FA2G2S1 (GP18) of IgG1 in 31 patients with AD compared to 23
age-matched controls in European ancestry35. In addition, Russell
et al found that the presence of Parkinson’s disease pathology in
Caucasian population was predominantly explained with a
reduced relative abundance of GP5, GP17, and an increased
relative abundance of GP843. We also detected decreasing GP14
and GP18 for dementia patients in Chinese population in this
study. However, other results are inconsistent with these studies.
Glycans do not have a direct genetic template, thus glycan
structures attached to proteins are determined by these complex
dynamic interactions including genetic and epigenetic factors44,45.
Therefore, the extensive differences in genetics or environmental
exposures among these ethnic studies may partly explain the
inconsistent associations between IgG Fc N-glycans and neurode-
generative diseases.
IgG mediates pro- and anti-inflammatory activities mainly
through the engagement of its constant region with distinct Fc
receptors46,47. Studies have shown that the decreasing sialylation
and core fucosylation as well as increasing the bisecting GlcNAc
contents within the Fc domain of IgG could activate its antibody-
dependent cell mediated cytotoxicity (ADCC) by reducing inhibi-
tion to ligate Fcγ-RIIIa on natural killer (NK) cells, macrophage, and
neutrophil, which can release proinflammatory factors (such as IL-
1β, IL-6, CRP, TNF-α, and IFN-γ)17,48–51. Thus, it may have the ability
to fine-tune FcγRIII-mediated from anti-inflammatory to proin-
flammatory effects20. These alterations in the IgG N-glycan
patterns may provide a switch from innate anti-inflammatory
activity in the steady state to adaptive proinflammatory effects
upon antigenic challenge47. Consistent with these, the inverse
correlation between sialylated (Sia), and core fucosylated IgG
glycoforms (Fuc and nFuc) and dementia in the present study was
somewhat expected. Increased bisecting GlcNAc N-glycan struc-
ture (Bis and nBis) was observed to be related with the state of
dementia in the present study. In addition, our findings that the
level of IgG sialylation (Sia), and core fucosylation (Fuc and nFuc)
decreased in MCI, while bisecting GlcNAc (Bis and nBis) increased
in MCI compared with NC group, suggesting that aberrant
glycosylation of IgG might contribute to pathogenesis of
dementia developed from MCI stage. These were further validated
Table 3. Associations of the normalized initial glycans.
GPs Dementia vs. NC Dementia vs. MCI MCI vs. NC
OR (95% CI)# p-adjusted q* OR (95% CI)# p-adjusted q* OR (95% CI)# p-adjusted q*
GP1 6.78 (3.01–15.29) 3.91E−06 1.72E−05 0.80 (0.54–1.18) 2.59E−01 3.97E−01 9.53 (4.24–21.41) 4.73E−08 1.04E−06
GP2 1.64 (1.07–2.52) 2.42E−02 3.80E−02 0.91 (0.62–1.34) 6.19E−01 6.81E−01 1.96 (1.25–3.08) 3.36E−03 8.21E−03
GP4 0.84 (0.58–1.22) 3.63E−01 4.70E−01 0.81 (0.55–1.21) 3.01E−01 4.13E−01 1.12 (0.78–1.60) 5.48E−01 5.74E−01
GP5 32.78 (8.31–129.27) 6.19E−07 4.50E−06 1.34 (0.85–2.11) 2.03E−01 3.67E−01 8.16 (2.95–22.58) 5.29E−05 2.91E−04
GP6 1.16 (0.78–1.71) 4.65E−01 5.11E−01 0.73 (0.49–1.09) 1.27E−01 2.53E−01 1.29 (0.94–1.77) 1.12E−01 1.36E−01
GP7 4.71 (2.29–9.67) 2.46E−05 6.77E−05 1.17 (0.79–1.73) 4.25E−01 5.43E−01 6.58 (3.02–14.34) 2.14E−06 2.35E−05
GP8 6.02 (3.05–11.89) 2.31E−07 3.10E−06 3.46 (2.02–5.94) 6.58E−06 1.45E−04 1.03 (0.74–1.43) 8.79E−01 8.79E−01
GP9 2.06 (1.37–3.10) 4.94E−04 1.09E−03 1.65 (1.12–2.44) 1.14E−02 3.57E−02 1.37 (0.98–1.93) 6.87E−02 8.89E−02
GP10 4.87 (2.66–8.90) 2.82E−07 3.10E−06 1.45 (1.00–2.10) 4.94E−02 1.21E−01 2.51 (1.54–4.11) 2.40E−04 1.06E−03
GP11 1.34 (0.62–2.90) 4.56E−01 5.11E−01 0.44 (0.25–0.77) 3.77E−03 1.38E−02 4.37 (1.95–9.79) 3.34E−04 1.22E−03
GP12 2.24 (1.39–3.63) 9.86E−04 1.97E−03 1.78 (1.09–2.88) 2.02E−02 5.55E−02 1.41 (0.89–2.24) 1.48E−01 1.71E−01
GP13 6.65 (2.55–17.36) 1.09E−04 2.66E−04 1.16 (0.80–1.68) 4.45E−01 5.43E−01 4.89 (2.32–10.30) 3.02E−05 2.21E−04
GP14 0.49 (0.30–0.78) 2.78E−03 5.10E−03 1.02 (0.69–1.50) 9.26E−01 9.26E−01 0.62 (0.43–0.88) 7.08E−03 1.56E−02
GP15 8.10 (3.53–18.61) 8.18E−07 4.50E−06 1.11 (0.78–1.57) 5.80E−01 6.72E−01 3.28 (1.65–6.53) 7.09E−04 2.23E−03
GP16 0.34 (0.21–0.55) 1.09E−05 4.00E−05 0.38 (0.23–0.63) 1.74E−04 1.28E−03 0.70 (0.50–0.99) 4.11E−02 6.45E−02
GP17 0.96 (0.63–1.45) 8.30E−01 8.33E−01 1.32 (0.85–2.05) 2.17E−01 3.67E−01 0.63 (0.42–0.93) 2.12E−02 3.58E−02
GP18 0.36 (0.22–0.57) 2.38E−05 6.77E−05 0.38 (0.22–0.66) 5.89E−04 3.24E−03 0.65 (0.46–0.92) 1.38E−02 2.52E−02
GP19 0.68 (0.39–1.20) 1.83E−01 2.52E−01 0.58 (0.30–1.15) 1.19E−01 2.53E−01 0.85 (0.62–1.17) 3.21E−01 3.53E−01
GP21 1.60 (0.98–2.62) 6.18E−02 9.06E−02 4.49 (2.15–9.38) 6.49E−05 7.14E−04 0.58 (0.33–1.00) 4.99E−02 7.32E−02
GP22 3.59 (1.40–9.19) 7.76E−03 1.31E−02 1.04 (0.69–1.56) 8.53E−01 8.93E−01 4.60 (1.85–11.43) 1.00E−03 2.75E−03
GP23 0.87 (0.64–1.20) 4.07E−01 4.98E−01 2.19 (1.31–3.64) 2.62E−03 1.15E−02 0.57 (0.37–0.87) 9.40E−03 1.88E−02
GP24 1.04 (0.73–1.48) 8.33E−01 8.33E−01 1.21 (0.86–1.70) 2.71E−01 3.97E−01 0.69 (0.47–1.02) 6.37E−02 8.75E−02
*q < 0.05: significant after correction for FDR (false discovery rate).
NC normal cognitive functioning, MCI mild cognitive impairment.
#Adjusting for the effects of age, sex, BMI, levels of education, history of malignant tumor, habit of salt intake, ischemic stroke, diabetes, hypertension and
dyslipidemia (adjusting for the above effects other than age and sex for dementia vs. NC).
p < 0.05 was considered statistically significant.
X. Zhang et al.
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by the significant differences of glycans between dementia and
MCI in the present study. Consequently, it could be hypothesized
that these distinct differences in IgG glycosylation pattern in MCI
might play a cascading role in the progression of dementia (Fig. 6).
Our findings corroborate the results that peripheral inflammation
correlates with dementia progress both prior to and following the
onset of the disease52–55. Levels of proinflammation factors in
serum were of significant differences among dementia, MCI and NC
groups in the present study, which further validated possibly direct
role of inflammation in the pathophysiology of MCI and dementia.
According to the research findings, central nervous system and
peripheral immune system exchanged in bi-directional ways56.
Activated peripheral immune cells that can penetrate the blood
brain barrier may regulate the pathogenesis of AD57,58. Inflamma-
tory processes play an important role in cognitive impairment for
the early phase of neurodegeneration which include inhibiting
angiogenic, neurotrophic and neuroprotective mechanisms59. The
high levels of proinflammatory factors (CRP, TNF-α, and IFN-γ) in the
dementia group showed that inflammation might be one of the
characteristics of dementia, which indicated that a chronic level of
inflammation was a known risk factor for dementia60. We also
found the anti-inflammatory (IL-10) state was positively correlated
with GP8 and GP14, while the proinflammation (CRP and IFN-γ)
factors were positively correlated with GP8. These findings
indicated that significant changes of IgG glycosylation profiles
might involve in the pathogenesis of dementia accompanying with
inflammation response. The aberrant peripheral IgG glycome of
individuals with dementia may reflect unknown modifications in
the intermediate cellular environment or interactions of the
biomolecules involved in B cell differentiation with the central
nervous system at a known interaction site (Fig. 6). Besides,
persistent inflammation related to atherosclerosis also might
provide a possible explanation for the pathogenesis of cerebrovas-
cular disease (such as hypertension and diabetes)61,62, implying an
increased risk of MCI and dementia.
The study has several major strengths. First, to the best of our
knowledge, this is the first study assessing IgG N-glycans levels in
relation to the risk of dementia. Furthermore, we analyzed the
association between IgG N-glycome and markers of inflammation
including anti-inflammatory (IL-4 and IL-10) as well as proin-
flammatory factors (CRP, TNF-α, IFN-γ, IL-1β, and IL-6), contributing
to explain the role of IgG glycosylation on dementia. However,
Fig. 2 Forest plots of the associations of the derived traits with MCI and dementia. Forest plots (a–c) show the odds ratios (ORs, black solid
square) with a horizontal lines representing 95% confidence intervals (CIs) for derived traits with MCI and dementia. Each of statistically
significant derived traits included study is represented by one row in the plots. The multiple logistic regression analysis was performed after
adjusting for age, sex, BMI, levels of education, history of malignant tumor, habit of salt intake, ischemic stroke, diabetes, hypertension, and
dyslipidemia (adjusting for the above effects other than age and sex for dementia vs. NC). a Dementia vs. NC, bMCI vs. NC, and c Dementia vs.
MCI. NC normal cognitive functioning, AD Alzheimer’s disease.
Fig. 3 The correlation coefficients in independent glycans.
Statistically significant associations between two glycans were
shown, p < 0.05, while the insignificant correlation coefficients were
shown using symbol (“×”) in the boxes. The positive correlations are
represented by blue color, while negative correlations are repre-
sented by red color.
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This study has some limitations. First, because our study design
was a case–control study, selection bias may still occur. In
addition, it is very difficult to be warranted to infer causal
relationships between the levels of IgG N-glycans and dementia.
Second, all patients were on their dementia medications
(donepezil, memantine, etc.), and it was not possible to distinguish
the effects of dementia medications on the IgG glycome. Third, it
is very hard to divide MCI into amnestic MCI (more likely due to
AD) and non-amnestic groups based on available data in present
study. Therefore, we failed to analyze and clarify why for some
glycans there seem to be stepwise changes from NC to MCI to AD
and for others MCI subjects have opposite trends from dementia
and AD subjects. Lastly, because the sample size was not large
enough, it was very hard to perform external cross-validation.
Therefore, further external cross-validation validations for these
novel biomarkers in cohort studies with large sample sizes and in
multi-ethnic populations are also needed.
In conclusion, this study showed that individuals with
dementia or on a pathway to dementia have an elevated
proinflammatory activity in peripheral blood which manifests
itself via the significant changes of IgG glycome profiles
(reflecting the decreased of sialylation and core fucosylation, as
well as the increased bisecting GlcNAc N-glycan structures).
Aberrant IgG glycosylation might contribute to the pathogenesis
of dementia because of the disequilibrium of anti- and
proinflammatory status. Although it is yet to be determined
whether the IgG glycosylation in blood plasma correlates with
those in cerebrospinal fluid, it is evident that IgG N-glycans might
contribute to the potential novel biomarkers for the neurode-
generative process risk assessment of dementia.
METHODS
Participants
Participants were recruited from the Beijing Geriatric Hospital, the
Emergency General Hospital, the Second Affiliated Hospital of Shandong
First Medical University, the Tai’an City Central Hospital and the Jidong Oil-
field Hospital of Chinese National Petroleum from May 2019 to January
2020. All participants were required to meet the following inclusion criteria:
(1) Age 60 or above; (2) Chinese Han population; (3) signed informed
consent prior to participation; and (4) blood sample available. Participants
with the following diseases were excluded: rheumatoid arthritis, systemic
lupus erythematosus and other rheumatoid immune disease. This study
was approved by the Ethics Committee of the Capital Medical University,
Beijing, China. The study was conducted according to the principles of the
Declaration of Helsinki. Written informed consents were obtained from all
participants before the study.
Diagnostic criteria
Participants were classified into three general categories: normal cognitive
functioning (NC), MCI and dementia. The Chinese version of the Montreal
Cognitive Assessment Basic (MoCA-BC) was used as a quick evaluation
scale to screen for MCI and distinguish MCI individuals from NC elderly
adults63. The optimal cut-off scores for MCI detection were determined
according to the education level. For individuals with 6 or fewer years of
education, the cut-off score was set as less than or equal to 19. For
individuals with 7–12 years of education were set as less than or equal to
22. For individuals with more than 12 years of education were set as less
than or equal to 24. Diagnostic criteria for dementia were based on the
fourth edition of the Diagnostic and Statistical Manual of Mental
Disorders64,65. The diagnosis of AD was based on the National Institute
of Neurological, Communicative Disorders and Stroke–Alzheimer Disease
and Related Disorders Association (NINCDS-ADRDA)66.
Fig. 4 The distribution of a panel of biomarkers (GP8, GP9 and GP14) within the dementia, mild cognitive impairment (MCI), and normal
cognitive functioning (NC) groups. The box plots show the distribution of GP8, GP9, and GP14 in dementia (blue), MCI (red), and NC (green)
groups. The following values correspond to center line, upper/lower bounds, and whisker max/min for dementia, MCI, and NC groups,
respectively: GP8: center line (median): 14.46, 12.35, 11.53; lower/upper bounds (P25/P75): 13.11/15.57, 10.02/13.91, 10.35/12.87; whiskers max/
min: 19.01/7.27, 21.96/3.09, 18.10/6.38; GP9: center line (median): 4.29, 3.35, 2.97; lower/upper bounds (P25/P75): 3.29/5.58, 2.00/5.06, 1.72/4.64;
whiskers max/min: 9.23/0.36, 7.78/0.47, 9.91/0.31; GP14: center line (median): 11.24, 13.02, 13.73; lower/upper bounds (P25/P75): 7.89/14.26,
8.74/16.56, 11.43/17.54; whiskers max/min: 23.87/0.01, 25.14/0.69, 30.89/4.34.
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Collection of blood sample and clinical traits
After overnight fasting, two tubes of blood samples (2 mL) were collected
in the morning by venipuncture. The tube without containing ethylene
diamine tetraacetic acid (EDTA) was used to separate serum to measure
the blood biochemistry indexes and inflammatory factors. The other tube
of the blood sample in vacuum negative pressure tubes containing EDTA
was centrifuged at 4000 rpm for 10 min to separate plasma. The plasma
was used to measure IgG glycans. Collected blood samples were
processed within 8 h and stored at −80 °C until further measurement.
Information on demographic (age, sex, ethnicity, and levels of
education) and clinical history were collected by a questionnaire.
Weight and height measurements were conducted when participants
had removed their shoes and other heavy objects from their pockets.
The body mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared. After the participants resting at
least 10 min in a sitting position, SBP (mmHg) and DBP (mmHg) were
measured twice on the right arm by trained nurses using a standard
mercury sphygmomanometer67. According to the guideline for the
prevention and control of dyslipidemia of adults in China, the
participants were grouped into dyslipidemia with total cholesterol
(TC) ≥ 6.2 mmol/L, or triglycerides (TG) ≥ 2.3 mmol/L, or high-density
lipoprotein cholesterol (HDL-C) < 1.0 mmol/L or low-density lipoprotein
cholesterol (LDL-C) ≥ 4.1 mmol/L68.
Measurement of inflammatory factors and IgG N-glycans
The levels of inflammatory factors (IL-1β, IL-4, IL-6, IL-10, CRP, TNF-α, and IFN-
γ) were measured using enzyme-linked immunosorbent assay (ELISA, R&D
Systems, Bio-Techne China Co. Ltd., Beijing, China) according to the kits
manufacturer’s instructions69. Take IL-6, for example. The standards, quality
controls and serum samples were incubated in the micro-titration 96-well
plate coated with polyclonal anti-human IL-6 antibody. Polyclonal anti-
human IL-6 antibody labeled with horseradish peroxidase (HRP) was added
to the wells and incubated with the immobilized antibody- IL-6 complex
after a thorough wash. The HRP-conjugated antibody would react with the
substrate and tetramethylbenzidine after another wash step. The reaction
was stopped by acidic solution. Absorbance (optical density) was measured
at 450 nm. The IL-6 concentration (mg/L) was interpolated from a four-
parameter logistic 4-PL standard curve generated with ELISAcalc software.
Each standard was estimated using the 4-PL curve-fit measurements.
The IgG was firstly isolated from human plasma as previously reported70.
After washing and equilibrating protein G monolithic plates, 50 μL of
plasma was diluted 10× with binding buffer (1× phosphate buffered saline,
pH= 7.4) which was applied to the protein G plates, and then washed
immediately. IgG was eluted with 1 mL of 0.1 M formic acid and neutralized
with 1 M ammonium bicarbonate instantly. The following step was that IgG
N-glycans were released and labeling was conducted. The released N-
glycans were labeled with 2-aminobenzamide which was applied to make
Fig. 5 The ROC curves for the IgG N-glycans (GP8, GP9, and GP14) as diagnostic biomarkers by 5-fold cross-validation using the random
forest classifier. The ROC curves are represented by purple color lines, while 95% confidence intervals (CIs) are represented by blue dotted
lines. a Dementia vs. NC, b AD vs. NC, c dementia vs. MCI, and d MCI vs. NC. NC normal cognitive functioning, MCI mild cognitive impairment,
AD Alzheimer’s disease.
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glycans visible by mixing with 2-aminobenzamide, dimethylsulfoxide,
glacial acetic acid, and 2-picoline borane. In the end, IgG N-glycans were
separated by hydrophilic interaction chromatography-UPLC into 24 IgG
glycan peaks (GPs)70. The glycan structures of the most abundant glycans
per peak were reported previously71.
All chromatograms were separated in the same manner into 24 peaks
and the amount of glycans in each peak was expressed as a percentage of
total integrated area as shown in Supplementary Table 1. The GP3 was
excluded from all the calculations because it was eluted with contaminant
in some samples that affected its value. In addition, the GP20 was also
eliminated as its glycan structure has not been determined. The specific 54
derived traits representing the relative abundances of galactosylation,
sialylation, bisecting N-acetylglucosamine (GlcNAc), and core fucosylation
were calculated by the remaining 22 directly measured glycans72. In
addition, Huff man et al. utilized another method to calculate overall
aspects of derived traits73 (Supplementary Table 2). Normalization of UPLC
data were detailed in previously published study70.
Statistical analyses
Demographic and clinical characteristics were represented as mean ±
standard deviation for continuous variables underlying the normal
distribution, otherwise the median (P25− P75) was used. The differences
of continuous variables among three groups were tested by one-way
analysis of variance or the Kruskal–Wallis test. Categorical variables were
represented as n (%), and the differences among the three groups were
tested by chi-square test or Fisher exact test.
Spearman correlations were used to calculate the correlation
coefficient (rs) among IgG glycans as well as between IgG glycans and
inflammatory factors. The multiple logistic regression analysis was
performed to identify each of 24 initial glycans related to dementia
after adjusting the effects of confounders (including BMI, levels of
education, history of malignant tumor, habit of salt intake, ischemic
stroke, diabetes, hypertension and dyslipidemia). For the multiple
corrections, the FDR (false discovery rate) was used based on the
Benjamini–Hochberg procedure (q)74. Then the Ridge and Stepwise
(including the direction of Forward and Backward) based on logistic
regression as well as Lasso regression were performed to reduce
dimension for significant glycans75–77. The intersection of the above
three methods was identified as a panel of biomarkers for the diagnosis
of dementia. Model performance was evaluated using the 5-fold cross-
validation78. Models were implemented using the random forest which
was an ensemble or collection of multiple decision tree models. This
panel of biomarkers simultaneously was evaluated performance for
other comparison groups (AD vs. NC, dementia vs. MCI, and MCI vs. NC,
respectively). Classifier accuracy was measured by using NMSE, MSE,
MAE, and the AUC with the receiver operating characteristic
(ROC) curve.
Data analysis was performed using SPSS Statistics version 25.0 for
Windows (IBM Corp., Armonk, NY, USA) and R version 3.4.3 (R Core Team,
2017). All reported p values were two-tailed. The q value is used to
represent the p value after correction for multiple testing and hence
q value < 0.05 and p < 0.05 were considered statistically significant.




IL-4 IL-10 CRP TNF-α IFN-γ IL-1β IL-6
GP1 −0.050 0.003 0.050 0.007 −0.009 −0.006 0.025 /
GP2 −0.053 −0.026 0.069 0.069 −0.055 0.007 −0.058 /
GP4 −0.080 −0.050 0.017 0.046 0.011 0.088 −0.005 /
GP5 0.004 −0.056 0.073 0.053 −0.017 0.053 −0.013 /
GP6 −0.070 0.018 −0.052 0.043 0.040 −0.036 0.066 /
GP7 −0.007 −0.017 0.016 0.016 −0.042 −0.007 −0.072 /
GP8 −0.008 0.163* 0.168** 0.087 0.138* 0.035 0.042 +$
GP9 0.046 0.036 −0.023 −0.009 0.005 0.041 −0.040 /
GP10 −0.049 0.133* 0.137* 0.092 0.097 0.014 0.063 +$
GP11 0.038 −0.061 −0.010 −0.031 −0.047 −0.012 −0.015 /
GP12 −0.023 0.011 −0.005 0.046 −0.029 0.024 −0.071 /
GP13 0.045 −0.014 −0.012 −0.042 −0.119 −0.051 −0.063 /
GP14 0.135* 0.055 −0.060 −0.025 0.034 −0.051 0.065 +$
GP15 −0.021 −0.013 −0.016 0.013 −0.064 −0.003 −0.024 /
GP16 0.068 −0.123 −0.069 −0.133* −0.092 −0.110 −0.028 −$
GP17 −0.057 0.002 0.011 −0.076 −0.072 −0.015 −0.092 /
GP18 0.050 −0.042 −0.102 −0.091 −0.048 −0.103 −0.001 /
GP19 −0.014 −0.060 −0.056 −0.063 −0.099 −0.065 −0.082 /
GP21 −0.033 −0.016 0.008 −0.013 0.017 0.008 −0.050 /
GP22 0.006 −0.053 0.000 −0.038 −0.070 0.005 −0.065 /
GP23 −0.004 −0.029 0.008 −0.074 −0.119 −0.009 −0.112 /
GP24 −0.019 −0.045 −0.064 −0.059 −0.009 −0.068 −0.047 /
IL-4 interleukin-4, IL-10 interleukin-10, CRP C-reactive protein, TNF-α tumor necrosis factor-alpha, IFN-γ interferon-gamma, IL-1β interleukin-1 beta,
IL-6 interleukin-6.
*Correlation is significant at the 0.05 level.
**Correlation is significant at the 0.01 level.
$There is at least one significant inflammation factor.
/The association between glycans and inflammation remains unclear.
+The association between glycans and inflammation is positive.
−The association between glycans and inflammation is negative.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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